CliffBio
small molecule

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

Loss of exclusivity—loss of exclusivity
CompanyGenus Lifesciences Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameBUTALBITAL, ACETAMINOPHEN AND CAFFEINE
Active ingredientACETAMINOPHEN; BUTALBITAL; CAFFEINE
Strength325MG/15ML;50MG/15ML;40MG/15ML
Dosage formSOLUTION
RouteORAL
ModalitySmall molecule
FDA approvalJanuary 2003
Marketing statusRX

More from Genus Lifesciences Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE patent cliff — loss of exclusivity — | CliffBio